Literature DB >> 26403770

We need a break: Bisphosphonates.

Ashish Jaiman1, Dhananjaya Sabat2, Sumit Arora1, Mahmoud A Hafez3.   

Abstract

Bone is a dynamic tissue. It remodels, thereby maintaining serum calcium, repairing micro damage and maintaining strength. A reduction in the strength of bone leads to osteoporosis that may manifest clinically as low energy vertebral and non-vertebral fractures. The bone strength, in turn, is determined by its material, structural properties and on its remodeling potential. Commonly, osteoporosis is objectively evaluated by 'T' and 'Z' scores and these are the indicators of bone density as determined by Dexa scan; these scores correlate inversely with the fracture risk. Quite often, we forget that Dexa scan results are not the only factors determining bone strength and the association between bone density and bone strength is not fixed, and is exemplified by the example of "osteopetrosis". The same issue is happening with the prolonged use of bisphosphonates (BP's).

Entities:  

Keywords:  Bisphosphonates; Osteoporosis

Year:  2013        PMID: 26403770      PMCID: PMC3880530          DOI: 10.1016/j.jcot.2013.01.010

Source DB:  PubMed          Journal:  J Clin Orthop Trauma        ISSN: 0976-5662


  48 in total

Review 1.  Statins and the joint: multiple targets for a global protection?

Authors:  Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Enrico Selvi; Sauro Lorenzini; Stefania Bisogno; Cosima Tatiana Baldari; Mauro Galeazzi; Franco Laghi-Pasini
Journal:  Semin Arthritis Rheum       Date:  2010-09-29       Impact factor: 5.532

Review 2.  Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease.

Authors:  P Chavassieux; E Seeman; P D Delmas
Journal:  Endocr Rev       Date:  2006-12-19       Impact factor: 19.871

3.  Bisphosphonates and atypical femoral fractures: a time for reflection.

Authors:  J E Compston
Journal:  Maturitas       Date:  2009-11-22       Impact factor: 4.342

4.  Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.

Authors:  H A Pols; D Felsenberg; D A Hanley; J Stepán; M Muñoz-Torres; T J Wilkin; G Qin-sheng; A M Galich; K Vandormael; A J Yates; B Stych
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

5.  Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Authors:  Joseph D Isaacs; Louis Shidiak; Ian A Harris; Zoltan L Szomor
Journal:  Clin Orthop Relat Res       Date:  2010-08-31       Impact factor: 4.176

6.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors:  Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

7.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 8.  Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment.

Authors:  Matthew R Allen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-11       Impact factor: 4.481

Review 9.  Update on the use of bisphosphonates in the management of postmenopausal osteoporosis by obstetricians-gynecologists.

Authors:  John A Sunyecz; Richard Derman
Journal:  Obstet Gynecol Surv       Date:  2007-06       Impact factor: 2.347

10.  Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.

Authors:  Takahiro Iizuka; Mitsuhiro Matsukawa
Journal:  Climacteric       Date:  2008-08       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.